联合检测癌胚抗原、糖类抗原19-9、糖类抗原242和糖类抗原50在可切除胃癌诊断及预后评估中的应用

Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.

作者信息

Tian Shu-Bo, Yu Jian-Chun, Kang Wei-Ming, Ma Zhi-Qiang, Ye Xin, Cao Zhan-Jiang, Yan Chao

机构信息

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China E-mail :

出版信息

Asian Pac J Cancer Prev. 2014;15(15):6295-300. doi: 10.7314/apjcp.2014.15.15.6295.

Abstract

Our aim was to investigate the value of combined detection of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA 242 and CA 50 in diagnosis and assessment of prognosis in consecutive gastric cancer patients. Clinical data including preoperative serum CEA, CA 19-9, CA 242, and CA 50 values and information on clinical pathological factors were collected and analyzed retrospectively. Univariate and multivariate survival analyses were used to explore the relationship between tumor markers and survival. Positive rates of tumor markers CEA, CA 19-9, CA 242 and CA 50 in the diagnosis of gastric cancer were 17.7, 17.1, 20.4 and 13.8%, respectively, and the positive rate for all four markers combined was 36.6%. Patients with elevated preoperative serum concentrations of CEA, CA 19-9, CA 242 and CA 50, had late clinical tumor stage and significantly poorer overall survival. Five-year survival rates in patients with elevated CEA, CA 19-9, CA 242 and CA 50 were 28.1, 25.8, 27.0 and 24.1%, respectively, compared with 55.0, 55.4, 56.4 and 54.5% in patients with these markers at normal levels (p<0.01). In multivariate Cox proportional hazards analyses, an elevated CA 242 level was determined to be an independent prognostic marker in gastric cancer patients. Combined detection of four tumor markers increased the positive rate for gastric cancer diagnosis. CA 242 showed higher diagnostic value and CA 50 showed lower diagnostic value. In resectable gastric carcinoma, preoperative CA 242 level was associated with disease stage, and was found to be a significant independent prognostic marker in gastric cancer patients.

摘要

我们的目的是研究联合检测血清癌胚抗原(CEA)、糖类抗原(CA)19-9、CA 242和CA 50在连续性胃癌患者诊断及预后评估中的价值。回顾性收集并分析临床资料,包括术前血清CEA、CA 19-9、CA 242和CA 50值以及临床病理因素信息。采用单因素和多因素生存分析来探讨肿瘤标志物与生存之间的关系。肿瘤标志物CEA、CA 19-9、CA 242和CA 50在胃癌诊断中的阳性率分别为17.7%、17.1%、20.4%和13.8%,四项标志物联合检测的阳性率为36.6%。术前血清CEA、CA 19-9、CA 242和CA 50浓度升高的患者,临床肿瘤分期较晚,总体生存率显著较低。CEA、CA 19-9、CA 242和CA 50升高的患者5年生存率分别为28.1%、25.8%、27.0%和24.1%,而这些标志物水平正常的患者5年生存率分别为55.0%、55.4%、56.4%和54.5%(p<0.01)。在多因素Cox比例风险分析中,CA 242水平升高被确定为胃癌患者的独立预后标志物。联合检测四项肿瘤标志物可提高胃癌诊断的阳性率。CA 242显示出较高的诊断价值,而CA 50显示出较低的诊断价值。在可切除的胃癌中,术前CA 242水平与疾病分期相关,并且被发现是胃癌患者的一个重要独立预后标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索